HOME >> MEDICINE >> NEWS
Use of estrogen by postmenopausal women does not increase risk of breast cancer

CHICAGO Postmenopausal women treated with estrogen therapy for seven years did not experience an increased risk of breast cancer, according to a study in the April 12 issue of JAMA.

The Women's Health Initiative (WHI) Estrogen-Alone trial, which randomized women with prior hysterectomy to conjugated equine estrogens (CEE) or placebo, was stopped earlier than planned because of increased stroke incidence and no reduction in risk of coronary heart disease. In contrast to substantial epidemiological evidence associating exogenous (originating externally) estrogens with increased breast cancer incidence, preliminary analyses found fewer breast cancers in women in the CEE group, prompting a detailed updated analysis of breast cancer incidence and mammographic reports.

Marcia L. Stefanick, Ph.D., of Stanford University, Stanford, Calif., and colleagues with the WHI study, analyzed the data from the CEE-alone group of the WHI study to determine the effects of CEE on breast cancers and mammographic findings. The study included 10,739 postmenopausal women aged 50 to 79 years with prior hysterectomy who were randomized to CEE or placebo at 40 U.S. clinical centers from 1993 through 1998. Mammography screenings and clinical breast examinations were performed at baseline and annually. All breast cancers diagnosed through February 29, 2004, are included. Participants received a dose of 0.625 mg/d of CEE or an identical-appearing placebo.

In an analyses of all events (n = 237 cases) occurring prior to intervention termination, after an average follow-up of 7.1 years, nonsignificant reductions were observed for invasive breast cancer (20 percent lower rate) and for total breast cancer (18 percent lower rate) in women randomized to CEE, when compared to the placebo group. The annualized rates were 0.28 (104 cases in the CEE group) and 0.34 (133 cases in the placebo group). In further analyses, fewer breast cancers with localized disease were diagnosed
'"/>

Contact: Susan Ipaktchian
650-725-5375
JAMA and Archives Journals
11-Apr-2006


Page: 1 2

Related medicine news :

1. COX inhibitors may weaken protective qualities of estrogen hormone therapy
2. Study describes action of estrogen in protecting bone
3. New path from estrogen to survival in breast cancer cells described
4. High estrogen levels associated with dementia in older men
5. Ultra low-dose estrogen shown safe for post-menopausal women
6. Gabapentin cools hot flashes as well as estrogen
7. Study uncovers significant functional differences of novel estrogen receptor
8. Early estrogen exposure leads to later prostate cancer risk
9. Long-term estrogen therapy linked to breast cancer risk
10. Low estrogen levels in men linked to increased risk for hip fracture
11. Benefit of chemotherapy in breast cancer depends on estrogen-receptor status

Post Your Comments:
(Date:5/30/2015)... The results of a 40+ year study ... potential to cause mesothelioma, regardless of the volume of ... the Surviving Mesothelioma website. , The study conducted ... Poland found that, among the 138 cases of mesothelioma ... all of them happened at plants that had, at ...
(Date:5/30/2015)... San Diego, CA (PRWEB) May 30, 2015 ... public is the lack of local healthcare options available. ... access to adequate healthcare. For those in rural areas ... those simply without health insurance or tired of paying ... announces new E-consults, connecting patients with licensed physicians via ...
(Date:5/30/2015)... 30, 2015 On Thursday, May ... Charles Simone and Dr. Evan Alley both of ... the Mesothelioma Experts’ series. The interview was part ... centers of excellence. Drs. Simone and Alley were ... Hesdorffer, with whom they discussed the mesothelioma program ...
(Date:5/30/2015)... May 30, 2015 Boston Scientific ... in punitive and compensatory damages to a transvaginal ... serious complications following implantation of the company’s Pinnacle ... rendered on May 28th in Delaware Superior Court, ... damages after the jury found that the implants ...
(Date:5/30/2015)... ProIntro Magnify contains 30 self-animating and minimalistic Titles including ... elegant opening title to any Final Cut Pro X ... layouts. ProIntro Magnify is created exclusively for Final Cut Pro ... Simply drag a preset into the FCPX timeline ... Inspector window then watch as ProIntro Magnify does the rest. ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2
(Date:5/30/2015)... N.J. , May 30, 2015  Eisai Inc. announced ... which showed that eribulin met the study,s primary endpoint evaluating ... adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma. ... Annual Meeting of the American Society of Clinical Oncology (ASCO) ... ASCO press conference on Saturday, May 30, and also in ...
(Date:5/30/2015)... IRVING, Tex. , May 30, 2015 /PRNewswire/ ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the utility of Caris Molecular ... in facilitating comparisons between tumors that share histological ... of the American Society of Clinical Oncology (ASCO) ...
(Date:5/29/2015)... OTTAWA , May 29, 2015 /CNW/ - Alliance ... Canada, is recalling the health product Galenic Health ... levels of lead for adolescents and children. The ... limits for children, but within acceptable limits for ... used to relieve digestive upset and disturbances. Alliance ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
Cached News: